Ascendis Pharma A (ASND) Non-Current Assets (2012 - 2026)

Ascendis Pharma A has reported Non-Current Assets for 15 years, with the latest figure at $1.0 billion in Q1 2026.

• Quarterly Non-Current Assets rose 600.59% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 600.59% YoY) and the FY2025 annual result came in at $225.3 million, up 81.29% from the prior year.
• Non-Current Assets rose to $1.0 billion in Q1 2026 per ASND's latest filing, from -$3.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.0 billion in Q1 2026 and troughed at -$3.9 million in Q4 2025.
• A 5-year average of $197.8 million and a median of $152.7 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets tumbled 864.46% in 2025, then surged 600.59% in 2026.
• Over 5 years, Non-Current Assets stood at $136.6 million in 2022, then decreased by 9.4% to $123.8 million in 2023, then tumbled by 100.33% to -$409272.0 in 2024, then sank by 864.46% to -$3.9 million in 2025, then soared by 26228.31% to $1.0 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $1.0 billion, -$3.9 million, and $160.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.